Zymeworks (ZYME) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
18 May, 2026Executive summary
The annual meeting will be held virtually on December 30, 2025, with stockholders of record as of November 3, 2025, eligible to vote on key proposals including director elections, executive compensation, and auditor ratification.
Proxy materials are distributed primarily via the Internet to reduce costs and environmental impact, with options for paper copies upon request.
Voting can be conducted online, by phone, or by mail, and a quorum requires at least 33 1/3% of voting power present or represented by proxy.
Voting matters and shareholder proposals
Stockholders will vote on electing three Class I directors, an advisory say-on-pay vote for executive compensation, and ratification of KPMG as auditors for 2025.
The board recommends voting FOR all director nominees, FOR the executive compensation advisory vote, and FOR auditor ratification.
Shareholders may submit proposals or director nominations for the 2026 annual meeting, following advance notice and procedural requirements.
Board of directors and corporate governance
The board consists of nine directors with staggered three-year terms, a majority of whom are independent under Nasdaq standards.
Recent changes include resignations and new appointments, with a focus on diversity and relevant industry experience.
Committees include audit, compensation, and nominating/governance, each with independent members and defined charters.
Stock ownership guidelines for non-management directors were adopted in September 2025, requiring 10,000 shares by September 2028.
Latest events from Zymeworks
- Annual meeting to vote on directors, executive pay, auditor, and highlight ESG and governance.ZYME
Proxy filing18 May 2026 - Key votes include director elections, executive pay, and auditor ratification at the 2024 meeting.ZYME
Proxy filing18 May 2026 - Q3 revenue up 73% on milestone and royalty gains, with narrowed net loss and strong cash runway.ZYME
Q3 202518 May 2026 - Virtual annual meeting on Dec 30, 2025, covers director elections, pay, and auditor ratification.ZYME
Proxy filing18 May 2026 - FDA Priority Review, $250M royalty loan, and robust pipeline drive long-term value.ZYME
Q1 202618 May 2026 - Robust pipeline advances and strong cash position drive a royalty-focused growth strategy.ZYME
The Citizens Life Sciences Conference 202615 May 2026 - Hybrid biotech-royalty model, strong pipeline, and $250M financing drive growth and flexibility.ZYME
TD Cowen 46th Annual Health Care Conference28 Apr 2026 - Strong financials and innovation drive growth, with key catalysts and pipeline advances ahead.ZYME
2026 Bloom Burton & Co. Healthcare Investor Conference21 Apr 2026 - Transitioning to a hybrid R&D and asset aggregation model, with strong cash and pipeline momentum.ZYME
25th Annual Needham Virtual Healthcare Conference15 Apr 2026